Omnio AB is a Swedish biotechnology company based in Umeå developing a plasminogen-based biologic therapy for hard-to-heal chronic wounds, with diabetic foot ulcers as its lead indication. Founded on research by Professor Tor Ny of Umeå University, the company is advancing a recombinant plasminogen drug candidate designed to restart the stalled wound-healing process, with potential applications in venous leg ulcers, burns and other chronic wound conditions. R&D operations are based in Umeå, while clinical operations and quality functions are coordinated from Copenhagen and Barcelona.
1
Round
1
Industry
4
Tags
Oct 2, 2026
Latest raise
Funding activity · 1 round
Oct 2, 2026
EUR 2.9M
Seed
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
